Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 2OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 67Carcinoma, Non-Small-Cell Lung 45Lung Neoplasms 42Lymphoma 36Prostatic Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Ovarian Neoplasms 27Uterine Cervical Neoplasms 23Central Nervous System Neoplasms 22Neoplasm Metastasis 21Fallopian Tube Neoplasms 21Colorectal Neoplasms 21Leukemia 20Neuroblastoma 17Head and Neck Neoplasms 17Rectal Neoplasms 16Brain Neoplasms 16Adenocarcinoma of Lung 16Sarcoma 15Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Colonic Neoplasms 14Burkitt Lymphoma 14Leukemia, Myeloid, Acute 13HIV Infections 13Urinary Bladder Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Multiple Myeloma 11Hodgkin Disease 11Astrocytoma 11

Interventions

ribociclib 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Has results × Cystadenocarcinoma, Serous × Clear all
NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled 19 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡